Less Ads, More Data, More Tools Register for FREE

Pin to quick picksINS.L Regulatory News (INS)

  • There is currently no data for INS

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

US Government Contract Extension

26 Mar 2014 07:01

RNS Number : 1889D
Instem plc
26 March 2014
 

26 March 2014

RNS Reach

Instem plc("Instem", or the "Company")

US Government Contract Extension

NIEHS extends use of Provantis Preclinical software across additional sites and users

Instem (AIM:INS), a leading provider of IT solutions to the global early development healthcare market, announces that the National Institute of Environmental Health Sciences (NIEHS), part of the US National Institutes of Health (NIH), has exercised the year two option for Instem's Provantis preclinical software suite via SaaS (Software-as-a-Service), supporting National Toxicology Program studies. It has also exercised options to add two further operational sites and 100 further Provantis users.

The value of this latest extension to the contract, which was signed in February 2013, is approximately $1.3 million and the potential remains to extend and expand the agreement up to a further 8 years, giving a possible total contract value for all 10 years of between $6.5m-$7.6m. Having also added two additional sites during 2013, there are now 6 sites licensed under the agreement. The contract includes the ability to licence usage at 6 additional sites (maximum 12 sites in total) on the same terms, which could result in a further material increase in revenue.

The National Toxicology Program (NTP) is an interagency program established in 1978 to coordinate toxicology research and development across the Department of Health and Human Services. The program was also created to strengthen the science base in toxicology, develop and validate improved testing methods and provide information about potentially toxic chemicals to health regulatory and research agencies, scientific and medical communities, and the public.

Headquartered at NIEHS, the NTP is managed by the NIEHS and supported by the United States Food and Drug Administration and the Centers for Disease Control and Prevention.

Phil Reason, CEO of Instem plc, commented, "The first twelve months under this important US government contract have gone very well and the renewal for the first option year marks an important contract milestone. We continue to see opportunities for further government related contracts and our performance under this NIEHS contract provides a valuable reference project.

"This long term contract provides funding for the development of the Provantis suite in areas specific to the National Toxicology Program, adding further depth to our market leading study management platform and positioning Instem well for anticipated contract extensions."

 

For further information, please contact:

Instem plc

+44 (0) 1785 825600

Phil Reason, CEO

Nigel Goldsmith, CFO

N+1 Singer (Nominated Adviser & Broker)

+44 (0) 20 7496 3000

Richard Lindley

Nick Owen

Newgate Threadneedle

+44 (0) 20 7653 9850

Caroline Forde

Fiona Conroy

 

About Instem

Instem is a leading supplier of IT applications to the early development healthcare market delivering compelling solutions for data collection, management and analysis across the R&D continuum. Instem applications are used by customers worldwide, meeting the rapidly expanding needs of life science and healthcare organisations for data-driven decision making leading to safer, more effective products.

Instem's established portfolio of software solutions increases client productivity by automating study-related processes while offering the unique ability to generate new knowledge through the extraction and harmonisation of actionable scientific information.

Instem supports over 400 clients through full service offices in the United States, United Kingdom and China with additional locations in India and a full service distributor based in Japan. 

 

To learn more about Instem solutions and its mission, please visit www.instem.com or its investor centre http://investors.instem.com/  

 

About NIEHSThe NIEHS supports research to understand the effects of the environment on human health and is part of the National Institutes of Health (NIH). Its mission is to reduce the burden of human illness and disability by understanding how the environment influences the development and progression of human disease.

For more information on environmental health topics, visit www.niehs.nih.gov.

The NIH - The Nation's Medical Research Agency - includes 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Services. It is the primary federal agency for conducting and supporting basic, clinical and translational medical research, and it investigates the causes, treatments, and cures for both common and rare diseases. For more information about NIH and its programs, visit www.nih.gov.

This project has been funded in whole or in part with Federal funds from the National Institute of Environmental Health Sciences, National Institutes of Health, Department of Health and Human Services, under Contract No. HHSN27320130004C.

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
NRAQKPDDDBKBKNB
Date   Source Headline
8th Sep 20232:15 pmRNSForm 8.3 - Instem plc
8th Sep 20232:00 pmRNSForm 8 (OPD) - Instem plc
8th Sep 20231:58 pmPRNForm 8.3 - Instem Plc
8th Sep 20239:50 amRNSForm 8.5 (EPT/RI)
7th Sep 20233:03 pmRNSForm 8.3 - Instem plc
7th Sep 20233:00 pmBUSForm 8.3 - INS LN
7th Sep 20231:54 pmPRNForm 8.3 - Instem Plc
7th Sep 202311:07 amRNSForm 8.3 - Instem Plc
7th Sep 202310:12 amRNSForm 8.5 (EPT/RI)
5th Sep 20236:00 pmRNSReplacement: Form 8 (OPD) - Instem plc
5th Sep 20234:15 pmRNSForm 8 (OPD) - Instem plc
5th Sep 20231:38 pmPRNForm 8.3 - Instem Plc
5th Sep 202310:48 amRNSForm 8.5 (EPT/RI)
5th Sep 20239:55 amRNSForm 8.3 - Instem Plc
4th Sep 20234:50 pmRNSForm 8.3 - Instem plc
4th Sep 20239:58 amRNSForm 8.5 (EPT/RI)
1st Sep 20233:00 pmBUSForm 8.3 - INS LN
1st Sep 20232:15 pmGNWForm 8.3 - Instem PLC
1st Sep 20231:29 pmPRNForm 8.3 - Instem Plc
1st Sep 202312:05 pmRNSForm 8.5 (EPT/RI)
1st Sep 202311:25 amRNSForm 8.3 - Instem plc
1st Sep 20237:00 amBUSForm 8.3 - Instem plc
31st Aug 20234:45 pmPRNRe-issue: Form 8.3 - Instem Plc
31st Aug 20233:00 pmBUSForm 8.3 - INS LN
31st Aug 202312:02 pmRNSForm 8.3 - Instem plc
31st Aug 202312:00 pmRNSForm 8.5 (EPT/RI) - Instem plc
31st Aug 202311:44 amGNWForm 8.3 - [Instem plc - Opening Declaration - 30 08 2023] - (CGAML)
31st Aug 202311:15 amRNSForm 8.3 - Instem PLC
31st Aug 202310:29 amGNWForm 8.3 - Instem PLC
31st Aug 202310:07 amRNSForm 8.3 - Instem Plc
31st Aug 202310:02 amBUSForm 8.3 - INSTEM PLC
31st Aug 202310:01 amRNSForm 8.3 - Instem Plc
31st Aug 20239:55 amRNSForm 8.3 - Instem plc
31st Aug 20239:44 amRNSForm 8.5 (EPT/RI)
31st Aug 20239:24 amRNSHolding(s) in Company
30th Aug 202312:09 pmRNSForm 8.3 - Instem plc
30th Aug 202311:26 amRNSForm 8.3 - Instem plc
30th Aug 202310:22 amBUSForm 8.3 - INSTEM PLC
30th Aug 202310:10 amRNSForm 8.3 - Instem Plc
30th Aug 20237:00 amRNSRecommended Cash Offer
15th Aug 20237:00 amRNSTrading Update
3rd Aug 20237:30 amRNSHolding(s) in Company
31st Jul 20231:32 pmRNSHolding(s) in Company
28th Jul 202310:00 amRNSExercise of Options, Issue of Equity & TVR
27th Jul 20231:15 pmRNSHolding(s) in Company
28th Jun 20237:00 amRNSResult of AGM
2nd Jun 20238:51 amRNSNotice of AGM & Posting of Annual Report
2nd Jun 20238:38 amRNSExercise of Options, Issue of Equity & TVR
18th May 20239:14 amRNSHolding(s) in Company
15th May 20237:01 amRNSFinal Results & Investor Presentation

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.